Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (321-330 of 342) with videos related to

Pageof 35
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 35

Showing results (321-330 of 342) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 35